{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:10:23Z","timestamp":1784999423550,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T00:00:00Z","timestamp":1292284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s11926-010-0154-6","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T18:00:35Z","timestamp":1292436035000},"page":"154-159","source":"Crossref","is-referenced-by-count":42,"title":["Quality of Care in Patients with Gout: Why is Management Suboptimal and What Can Be Done About It?"],"prefix":"10.1007","volume":"13","author":[{"given":"N. Lawrence","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,14]]},"reference":[{"key":"154_CR1","unstructured":"Edwards NL. Crystal deposition diseases. In Cecil\u2019s Textbook of Medicine. 24th Edition, 2010."},{"key":"154_CR2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2007.078469","volume":"66","author":"E Pascual","year":"2007","unstructured":"Pascual E, Sivera F, Why is gout so poorly managed? Ann Rheum Disease 2007: 66;1269\u20131270.","journal-title":"Ann Rheum Disease"},{"key":"154_CR3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7326\/0003-4819-54-3-452","volume":"54","author":"DJ McCarty","year":"1961","unstructured":"McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54:452\u201360.","journal-title":"Ann Intern Med"},{"key":"154_CR4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00002281-199909000-00020","volume":"11","author":"N Schlesinger","year":"1999","unstructured":"Schlesinger N, Baker DG, Schumacher HR Jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 1999; 11:441\u20135.","journal-title":"Curr Opin Rheumatol"},{"key":"154_CR5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E et al.: EULAR evidence-based recommendations for gout. Part I. Diagnosis. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Disease 2006; 65:1301\u201311.","journal-title":"Ann Rheum Disease"},{"key":"154_CR6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","volume":"44","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005: 44;1038\u20131042.","journal-title":"Rheumatology"},{"key":"154_CR7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/ard.2007.070755","volume":"66","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Disease 2007: 66;1311\u20131315.","journal-title":"Ann Rheum Disease"},{"key":"154_CR8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s100670050005","volume":"19","author":"B Pal","year":"2000","unstructured":"Pal B, Foxall M, Dysart T, et al. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000: 19;21\u201325.","journal-title":"Clin Rheumatol"},{"key":"154_CR9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","volume":"6","author":"R Terkeltaub","year":"2010","unstructured":"\u2022\u2022Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6:30\u201338. Evidence-based strategies for using established and inexpensive drugs are defined, and recommendations for the use of novel targeted approaches are outlined in this review.","journal-title":"Nat Rev Rheumatol"},{"key":"154_CR10","volume-title":"Arthritis and Allied Conditions","author":"NL Edwards","year":"2009","unstructured":"Edwards NL. Management of Hyperuricemia. In, Arthritis and Allied Conditions\u00a016th Edition (ed WJ Koopman) Williams and Wilkins (Baltimore), 2009.","edition":"16"},{"key":"154_CR11","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/art.23803","volume":"58","author":"NL Edwards","year":"2008","unstructured":"\u2022\u2022 Edwards NL. Treatment failure gout: a moving target. Arthritis Rheum 2008: 58;2587\u20132590. Established ULTs allopurinol and probenecid have historically been misunderstood and misused by physicians, leading to the belief that failures in treating gout were the fault of the medication and not of the prescribing habits.","journal-title":"Arthritis Rheum"},{"key":"154_CR12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CDA Sarawate","year":"2006","unstructured":"Sarawate CDA, Brewer KK, Yang W et al. Gout medication treatment patterns and adherence to standards of care from managed care perspective. Mayo Clin Proc 2006: 81;925\u2013934.","journal-title":"Mayo Clin Proc"},{"key":"154_CR13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","volume":"57","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007: 57;1324\u20131328.","journal-title":"Arthritis Rheum"},{"key":"154_CR14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.22767","volume":"57","author":"JA Singh","year":"2007","unstructured":"Singh JA, Hodges JS, Toscano JP et al. Quality of care for gout in the U needs improvement. Arthritis Rheum 2007: 57;822\u2013829.","journal-title":"Arthritis Rheum"},{"issue":"suppl 47","key":"154_CR15","first-page":"S114","volume":"256","author":"TR Mikuls","year":"2007","unstructured":"Mikuls TR. Quality of care in gout: from measurement to improvement. Clin Exp Rheumatol 2007: 256(suppl 47); S114\u2013S119.","journal-title":"Clin Exp Rheumatol"},{"key":"154_CR16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.20102","volume":"50","author":"TR Mikuls","year":"2004","unstructured":"Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004: 50;937\u2013943.","journal-title":"Arthritis Rheum"},{"key":"154_CR17","first-page":"104","volume":"33","author":"T Neogi","year":"2006","unstructured":"Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006:33; 104\u2013109.","journal-title":"J Rheumatol"},{"key":"154_CR18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/ard.2006.051649","volume":"65","author":"LR Harrold","year":"2006","unstructured":"Harrold LR, Yood RA, Mikuls TR et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Disease 2006; 65:1368\u201372.","journal-title":"Ann Rheum Disease"},{"key":"154_CR19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","volume":"12","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Patel PA, Schumacher HR et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12:61\u20135.","journal-title":"J Clin Rheumatol"},{"key":"154_CR20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II. Management: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Disease 2006; 65:1312\u201324.","journal-title":"Ann Rheum Disease"},{"key":"154_CR21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1445-5994.2000.tb00857.x","volume":"30","author":"L Stamp","year":"2000","unstructured":"Stamp L, Gow P, Sharples K et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000; 30:567\u201372.","journal-title":"Aust N Z J Med"},{"key":"154_CR22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Disease 1998; 57:545\u2013549.","journal-title":"Ann Rheum Disease"},{"key":"154_CR23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"K Hande","year":"1984","unstructured":"Hande K, Noone R, Stone W. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47\u201356.","journal-title":"Am J Med"},{"key":"154_CR24","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33: 1646\u20131650.","journal-title":"J Rheumatol"},{"key":"154_CR25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","volume":"60","author":"J Vazquez-Mellado","year":"2001","unstructured":"Vazquez-Mellado J, Meono Morales E, Pacheo-Tena C, et al. Relationship between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Disease 2001; 60:981\u2013983.","journal-title":"Ann Rheum Disease"},{"key":"154_CR26","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"M Becker","year":"2005","unstructured":"Becker M, Schumacher HJ, Wortmann R et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450\u201361.","journal-title":"N Engl J Med"},{"key":"154_CR27","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","volume":"67","author":"J Singh","year":"2008","unstructured":"\u2022\u2022 Singh J, Strand V. Gout is associated with more comorbidity, poorer health-related quality of life and higher health care utilization in US veterans. Ann Rheum Disease 2008; 67:1310\u20131316. This population-based, health-related quality-of-life assessment in US veterans with gout showed greater health care use, functional disability, and 1-year unadjusted mortality rates compared with non-gouty veterans.","journal-title":"Ann Rheum Disease"},{"key":"154_CR28","first-page":"577","volume":"28","author":"J Li-Yu","year":"2001","unstructured":"Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28:577\u201380.","journal-title":"J Rheumatol"},{"key":"154_CR29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321\u20135.","journal-title":"Arthritis Rheum"},{"key":"154_CR30","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450\u201361.","journal-title":"N Engl J Med"},{"key":"154_CR31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","volume":"5","author":"F Perez-Ruiz","year":"1999","unstructured":"Perez-Ruiz F, Calabozo M. Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999; 5:49\u201355.","journal-title":"J Clin Rheumatol"},{"key":"154_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000045783","volume":"86","author":"F Perez-Ruiz","year":"2000","unstructured":"Perez-Ruiz F, Calabrozo M, Herrero-Beites AM, Garcia-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000; 86:287\u201391.","journal-title":"Nephron"},{"key":"154_CR33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"Y-P Siu","year":"2006","unstructured":"Siu Y-P, Leung KT, Tong MKH, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kid Disease. 2006; 47:51\u201359.","journal-title":"Am J Kid Disease"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0154-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0154-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0154-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T03:27:02Z","timestamp":1559878022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0154-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,14]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["154"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0154-6","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,14]]}}}